164 related articles for article (PubMed ID: 20730486)
21. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
22. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.
Hadji P; Asmar L; van Nes JG; Menschik T; Hasenburg A; Kuck J; Nortier JW; van de Velde CJ; Jones SE; Ziller M
J Cancer Res Clin Oncol; 2011 Jun; 137(6):1015-25. PubMed ID: 21170551
[TBL] [Abstract][Full Text] [Related]
23. Bone safety of aromatase inhibitors versus tamoxifen.
Lønning PE
Int J Gynecol Cancer; 2006; 16 Suppl 2():518-20. PubMed ID: 17010062
[TBL] [Abstract][Full Text] [Related]
24. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
Garrone O; Bertelli G; Principe E; Lewis PD; Occelli M; Miraglio E; Merlano MC
Tumori; 2014; 100(6):620-4. PubMed ID: 25688495
[TBL] [Abstract][Full Text] [Related]
25. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
26. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.
Kalder M; Hans D; Kyvernitakis I; Lamy O; Bauer M; Hadji P
J Clin Densitom; 2014; 17(1):66-71. PubMed ID: 23562130
[TBL] [Abstract][Full Text] [Related]
27. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Szijgyarto Z; Flach KD; Opdam M; Palmieri C; Linn SC; Wesseling J; Ali S; Bliss JM; Cheang MCU; Zwart W; Coombes RC
Breast Cancer Res Treat; 2019 May; 175(1):149-163. PubMed ID: 30680659
[TBL] [Abstract][Full Text] [Related]
28. ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Khachidze N; Giorgadze E; Tsagareli M
Georgian Med News; 2017 Jan; (262):39-42. PubMed ID: 28252426
[TBL] [Abstract][Full Text] [Related]
29. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Lancet; 2007 Feb; 369(9561):559-70. PubMed ID: 17307102
[TBL] [Abstract][Full Text] [Related]
30. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Goss PE; Hadji P; Subar M; Abreu P; Thomsen T; Banke-Bochita J
Breast Cancer Res; 2007; 9(4):R52. PubMed ID: 17692126
[TBL] [Abstract][Full Text] [Related]
31. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
32. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy.
Hadji P; Kauka A; Bauer T; Tams J; Hasenburg A; Kieback DG
Climacteric; 2012 Oct; 15(5):460-6. PubMed ID: 22321061
[TBL] [Abstract][Full Text] [Related]
33. Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
Mouridsen HT
J Clin Oncol; 2004 Sep; 22(18):3833-4. PubMed ID: 15365083
[No Abstract] [Full Text] [Related]
34. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.
Geisler J; Lønning PE; Krag LE; Løkkevik E; Risberg T; Hagen AI; Schlichting E; Lien EA; Ofjord ES; Eide GE; Polli A; di Salle E; Paolini J
Eur J Cancer; 2006 Nov; 42(17):2968-75. PubMed ID: 16963261
[TBL] [Abstract][Full Text] [Related]
35. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
[TBL] [Abstract][Full Text] [Related]
36. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
[TBL] [Abstract][Full Text] [Related]
37. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.
Lundkvist J; Wilking N; Holmberg S; Jönsson L
Breast Cancer Res Treat; 2007 May; 102(3):289-99. PubMed ID: 17033927
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant treatment of breast cancer with exemestane.
Tanvetyanon T
N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
[No Abstract] [Full Text] [Related]
40. Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial.
Bossart M; Becker M; Hadji P; Kieback DG; Hasenburg A
Anticancer Res; 2012 Sep; 32(9):3933-8. PubMed ID: 22993340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
